143 related articles for article (PubMed ID: 15546204)
1. In vitro cytotoxicity and in vivo distribution after direct delivery of PEG-camptothecin conjugates to the rat brain.
Fleming AB; Haverstick K; Saltzman WM
Bioconjug Chem; 2004; 15(6):1364-75. PubMed ID: 15546204
[TBL] [Abstract][Full Text] [Related]
2. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of camptothecin and polymer-conjugated camptothecin in tumor spheroids and solid tumors.
Ying V; Haverstick K; Page RL; Saltzman WM
J Biomater Sci Polym Ed; 2007; 18(10):1283-99. PubMed ID: 17939886
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic evaluation of a novel in situ forming poly(ethylene glycol)-based hydrogel for the controlled delivery of the camptothecins.
Lalloo A; Chao P; Hu P; Stein S; Sinko PJ
J Control Release; 2006 May; 112(3):333-42. PubMed ID: 16650910
[TBL] [Abstract][Full Text] [Related]
6. Conjugation to increase treatment volume during local therapy: a case study with PEGylated camptothecin.
Haverstick K; Fleming A; Mark Saltzman W
Bioconjug Chem; 2007; 18(6):2115-21. PubMed ID: 17935287
[TBL] [Abstract][Full Text] [Related]
7. A novel polyrotaxane-based intracellular delivery system for camptothecin: in vitro feasibility evaluation.
Moon C; Kwon YM; Lee WK; Park YJ; Chang LC; Yang VC
J Biomed Mater Res A; 2008 Jan; 84(1):238-46. PubMed ID: 17607767
[TBL] [Abstract][Full Text] [Related]
8. Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs.
Conover CD; Greenwald RB; Pendri A; Shum KL
Anticancer Drug Des; 1999 Dec; 14(6):499-506. PubMed ID: 10834271
[TBL] [Abstract][Full Text] [Related]
9. Molecular targeting of BCL2 and BCLXL proteins by synthetic BCL2 homology 3 domain peptide enhances the efficacy of chemotherapy.
Dharap SS; Chandna P; Wang Y; Khandare JJ; Qiu B; Stein S; Minko T
J Pharmacol Exp Ther; 2006 Mar; 316(3):992-8. PubMed ID: 16291730
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay.
Gunaseelan S; Debrah O; Wan L; Leibowitz MJ; Rabson AB; Stein S; Sinko PJ
Bioconjug Chem; 2004; 15(6):1322-33. PubMed ID: 15546199
[TBL] [Abstract][Full Text] [Related]
11. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.
Andersson L; Davies J; Duncan R; Ferruti P; Ford J; Kneller S; Mendichi R; Pasut G; Schiavon O; Summerford C; Tirk A; Veronese FM; Vincenzi V; Wu G
Biomacromolecules; 2005; 6(2):914-26. PubMed ID: 15762660
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery.
Cirpanli Y; Bilensoy E; Lale Doğan A; Caliş S
Eur J Pharm Biopharm; 2009 Sep; 73(1):82-9. PubMed ID: 19442723
[TBL] [Abstract][Full Text] [Related]
13. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting.
Brigger I; Morizet J; Aubert G; Chacun H; Terrier-Lacombe MJ; Couvreur P; Vassal G
J Pharmacol Exp Ther; 2002 Dec; 303(3):928-36. PubMed ID: 12438511
[TBL] [Abstract][Full Text] [Related]
14. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
[TBL] [Abstract][Full Text] [Related]
15. Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma.
Sarapa N; Britto MR; Speed W; Jannuzzo M; Breda M; James CA; Porro M; Rocchetti M; Wanders A; Mahteme H; Nygren P
Cancer Chemother Pharmacol; 2003 Nov; 52(5):424-30. PubMed ID: 12904897
[TBL] [Abstract][Full Text] [Related]
16. Surface-functionalized ultrasmall superparamagnetic nanoparticles as magnetic delivery vectors for camptothecin.
Cengelli F; Grzyb JA; Montoro A; Hofmann H; Hanessian S; Juillerat-Jeanneret L
ChemMedChem; 2009 Jun; 4(6):988-97. PubMed ID: 19347834
[TBL] [Abstract][Full Text] [Related]
17. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.
Koo OM; Rubinstein I; Onyuksel H
Nanomedicine; 2005 Mar; 1(1):77-84. PubMed ID: 17292061
[TBL] [Abstract][Full Text] [Related]
18. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
[TBL] [Abstract][Full Text] [Related]
19. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin.
Hong M; Zhu S; Jiang Y; Tang G; Pei Y
J Control Release; 2009 Jan; 133(2):96-102. PubMed ID: 18840485
[TBL] [Abstract][Full Text] [Related]
20. Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation.
Paranjpe PV; Chen Y; Kholodovych V; Welsh W; Stein S; Sinko PJ
J Control Release; 2004 Nov; 100(2):275-92. PubMed ID: 15544875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
